“…Replacement therapy, with the administration of the missing factor, remains a cornerstone in the management of congenital hemophilia, to treat both bleeding and prophylactically [5]. Patients with congenital HA and HB have a variety of therapeutic options, including gene and cellular therapies [6,7]. Progressive joint disease, the development of inhibitors, increased risk of cardiovascular disease (CVD), infections, and severe bleeding constitute complications of these clinical entities, leading to increased mortality and morbidity [8][9][10][11][12].…”